Medicine choices in opioid substitution treatment

AI Summary

The UK Department of Health and Social Care (DHSC) has issued supplemental clinical guidance to update the 2017 Orange Book regarding opioid substitution treatment. This update, developed by a clinical expert group, addresses changes in evidence and practice since the previous standards were set. The regulatory framework relies on existing National Institute for Health and Care Excellence (NICE) guidelines, including CG52 for detoxification and TA114 for methadone and buprenorphine management. While the document does not report on specific company inspections or violations, it addresses the issue of outdated protocols by providing refined instructions for prescribing oral methadone and buprenorphine. Required actions for medical practitioners involve integrating this supplementary guidance with original Orange Book protocols when treating opioid dependence. This ensures that prescribing practices for substitute medications remain current and evidence-based. Furthermore, the DHSC announced that specific guidance regarding long-acting buprenorphine injections will be released in 2025. Clinicians are expected to adhere to these updated standards to maintain high levels of care and safety in substance misuse management across the United Kingdom.